 |
|
Frontal Lobe Function in Progressive Supranuclear Palsy
Jordan Grafman, PhD;
Irene Litvan, MD;
Claudia Gomez, MA;
Thomas N. Chase, MD
Arch Neurol. 1990;47(5):553-558.
Abstract
• Performance on tasks evaluating "executive and attentional" processes presumably subserved by prefrontal cortex were compared in patients with progressive supranuclear palsy and with age- and education-matched control subjects. The results indicated that patients with progressive supranuclear palsy were particularly impaired when a task required sequential movements, conceptual shifting, monitoring the frequency with which stimuli are presented, or rapid retrieval of verbal knowledge. These deficits could not simply be accounted for by slowed information processing or by a deficit in representational knowledge. Conceivably, "weak activation" of frontal lobe representational knowledge characterized by an observed attentional deficit results in the neuropsychological impairments noted in patients with progressive supranuclear palsy. The oral administration of physostigmine, under double-blind placebo-controlled conditions, did not facilitate executive or attentional performance as evaluated by our tasks.
Author Affiliations
From the Cognitive Neuroscience Unit, Medical Neurology Branch (Dr Grafman) and Experimental Therapeutics Branch (Drs Litvan and Chase and Ms Gomez), National Institute of Neurological Disorders and Stroke, Bethesda, Md.
Footnotes
Accepted for publication September 29, 1989.
The opinions and assertions contained herein are the private views of the authors, and are not to be construed as official or necessarily reflecting the views of the National Institutes of Health, the United States Public Health Service, the Department of Health and Human Services, or the Uniformed Services University of the Health Sciences.
Reprint requests to the Cognitive Neuroscience Unit, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10, Room 5C422, Bethesda, MD 20892 (Dr Grafman).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Chapter 40 Movement disorders
Fletcher
Brain's Diseases of the Nervous System 2009;12:med-9780198569381-chapter-med-9780198569381-chapter.
ABSTRACT
| FULL TEXT
Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy
Brenneis et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:246-249.
ABSTRACT
| FULL TEXT
Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan et al.
Neurology 2001;57:467-473.
ABSTRACT
| FULL TEXT
Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy
Soliveri et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:313-318.
ABSTRACT
| FULL TEXT
Progressive supranuclear palsy
Rehman
Postgrad. Med. J. 2000;76:333-336.
ABSTRACT
| FULL TEXT
PET measures of benzodiazepine receptors in progressive supranuclear palsy
Foster et al.
Neurology 2000;54:1768-1773.
ABSTRACT
| FULL TEXT
Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy
Kertzman et al.
Arch Neurol 1990;47:1346-1350.
ABSTRACT
|
